Cancer immunotherapy in routine cost‐effective cancer care?
Abstract Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable appro...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2018-10-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201809660 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850203491898753024 |
|---|---|
| author | Sir Marc Feldmann |
| author_facet | Sir Marc Feldmann |
| author_sort | Sir Marc Feldmann |
| collection | DOAJ |
| description | Abstract Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable approach in generating in situ T cells reprogrammed with chimeric antigen receptors (CARs) (Pfeiffer et al, 2018). |
| format | Article |
| id | doaj-art-767a1f5f370f4501ace3cfcfa65c0afc |
| institution | OA Journals |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2018-10-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-767a1f5f370f4501ace3cfcfa65c0afc2025-08-20T02:11:30ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842018-10-0110111210.15252/emmm.201809660Cancer immunotherapy in routine cost‐effective cancer care?Sir Marc Feldmann0Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of OxfordAbstract Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable approach in generating in situ T cells reprogrammed with chimeric antigen receptors (CARs) (Pfeiffer et al, 2018).https://doi.org/10.15252/emmm.201809660 |
| spellingShingle | Sir Marc Feldmann Cancer immunotherapy in routine cost‐effective cancer care? EMBO Molecular Medicine |
| title | Cancer immunotherapy in routine cost‐effective cancer care? |
| title_full | Cancer immunotherapy in routine cost‐effective cancer care? |
| title_fullStr | Cancer immunotherapy in routine cost‐effective cancer care? |
| title_full_unstemmed | Cancer immunotherapy in routine cost‐effective cancer care? |
| title_short | Cancer immunotherapy in routine cost‐effective cancer care? |
| title_sort | cancer immunotherapy in routine cost effective cancer care |
| url | https://doi.org/10.15252/emmm.201809660 |
| work_keys_str_mv | AT sirmarcfeldmann cancerimmunotherapyinroutinecosteffectivecancercare |